Sponsor:
Massachusetts General Hospital
Code:
NCT06525623
Conditions
Cirrhosis, Liver
Acute Kidney Injury
Hepatorenal Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Recommendation: No Further Resuscitation
Recommendation: Resuscitation with Crystalloid
Recommendation: Resuscitation with Colloid
Recommendation: Standard of Care IV Albumin
Brief summary:
Conditions
Cirrhosis, Liver
Acute Kidney Injury
Hepatorenal Syndrome
Study ID
NCT06525623
Start date
Sep 12, 2024
Status verified date
Mar, 2026
Completion date
May 1, 2027
Anticipated
Primary completion date
Mar 1, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
50 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: VAGA Group
placebo comparator: Standard of Care
Interventions
Recommendation: No Further Resuscitation
Recommendation: Resuscitation with Crystalloid
Recommendation: Resuscitation with Colloid
Recommendation: Standard of Care IV Albumin
Primary outcome measure
Locations
Massachusetts General Hospital
Recruiting
Boston, Massachusetts, United States, 02114
Contacts
Andrew S Allegretti, MD, MSc
aallegretti@mgh.harvard.eduPrincipal Investigator:
Andrew S Allegretti, MD Msc
Sponsor
Massachusetts General Hospital
Last update posted
Mar 13, 2026
Last verified
Mar, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-03-13.